Navigation Links
Proper cleat choice gives turf injuries the boot
Date:4/30/2013

ROSEMONT, Ill.Injury on the playing field often is caused by the interaction between the athlete's shoe and the field surface. In a literature review appearing in the May 2013 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), researchers shed light on the evolution of synthetic playing surfaces. The study summarizes the existing research on artificial turf and the role of shoe-surface interface in injury.

Synthetic surfaces were introduced in the 1960s to improve play surface durability and accessibility, and to minimize field maintenance. Newer, "third generation" artificial surfaces behave more like grass and soil, but continue to be associated with injuries to the foot, ankle, toe and knee, in addition to concussions. Characteristics of the play surface directly affect how much energy is absorbed by the athlete upon impact.

The key to minimizing injuries on natural and artificial playing fields may be to understand the interplay between different types of athletic shoes, specific sports and field surfaces.

"Optimal shoe-playing surface conditions may be level and sport-specific," said orthopaedic surgeon and lead study author Mark C. Drakos, MD. "The shoe-playing surface interface is a modifiable risk factor for injury, and further research is needed to improve playing conditions for athletes of all levels."

Determining the shoe-playing surface interface is complex and challenging as it is influenced by human factors (i.e., the athlete's body weight, velocity and acceleration, deceleration, loading rate, and angle of the foot and height before contact), shoe factors (i.e., sole type and cleat/stud material of footwear, and number and size of cleats and cleat configuration), type of playing surface, and related environmental factors.

Other article highlights:

  • Most types of shoes have higher peak torque (foot movement and movement force) on artificial turf than on natural turf.

  • Sole material and cleat pattern and shape may affect torque. For example, shoes with small cleats place the lowest amount of pressure on the foot, and may potentially minimize the incidence of foot stress fractures on artificial surfaces.

  • Because of constant changes in both the athletic shoe market and artificial surfaces, much of the existing research on the shoe-playing surface is outdated.

"The role of the shoe surface interface in the development of lower extremity injuries continues to be clarified," said Dr. Drakos. Optimal shoe-playing surfaces are most likely level- and sport-specific. The shoe-playing surface interface is a modifiable risk factor for injury and further research is needed to improve playing conditions for all athletes.


'/>"/>

Contact: Kayee Ip
ip@aaos.org
847-384-4035
American Academy of Orthopaedic Surgeons
Source:Eurekalert

Related medicine news :

1. Imprelis Lawsuit Representing Multiple Property Owners Alleging Imprelis Seriously Damaged Their Trees and Other Plant Life Filed By Wright & Schulte
2. Class Action Imprelis Lawsuit Filed on Behalf of Multiple Property Owners Who Allege Imprelis Use Caused Extensive Tree Damage and Death, Reports Wright & Schulte
3. New studies explore mangos potential health-affirming properties
4. More evidence berries have health-promoting properties
5. BOMI International and Transwestern Partner to Offer Property and Facility Staff Skill-Enhancing Education Programs
6. Waterfront Properties’ Palm Beach Gardens Golf Community Debuts New Spa
7. Waterfront Properties Congratulates Champions of Charity from Admiral’s Cove, Willoughby Golf Club
8. Study: Research reveals protective properties of influenza vaccines
9. QCI Mold and Water Damage Now Distributes Hydroxyl Generators to Improve Air Quality in Commercial and Residential Properties
10. Lyme Disease Prevention Begins with Proper Tick Identification and Timely Removal.
11. hCGTreatments / Diet Doc hCG Diet and Weight Loss Plans Seeks Intellectual Property Protection for Their Prescription hCG Diets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... Louis, Missouri (PRWEB) , ... May 26, 2016 ... ... cost, quality and clinical outcomes, hosted members and suppliers for its inaugural Member ... a focus on their mission of elevating the operational health of America’s healthcare ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... that has a significant negative impact on long-term patient survival, reports a team ... results, published online this week in the Journal of Thoracic and Cardiovascular Surgery, ...
(Date:5/26/2016)... ... , ... An April Gallup survey found rising health care costs to be ... Health Senior Living (SHSL) may not share those same worries thanks to a ... the year, while holding the line on increasing their contributions, including premiums, deductibles and ...
(Date:5/26/2016)... , ... May 26, 2016 , ... The Lung ... host a six-week smoking cessation class starting June 6 at their clinic in downtown ... http://www.gnahec.org . , Additionally, the Lung Institute has created a free downloadable 4 Week ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 ... 2016"market research report that provides an overview on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
(Date:5/24/2016)... , May 24, 2016 Celsion Corporation ... development company, today provided an update on its ... clinical trial combining GEN-1, the Company,s DNA-based immunotherapy, ... of newly-diagnosed patients with advanced ovarian cancer who ... surgery.  GEN-1 is an IL-12 DNA plasmid vector ...
Breaking Medicine Technology: